What is biotech funding and why does it matter for CFOs?
Biotech funding is the combined use of Ireland’s R&D tax credit and non-dilutive biotech grants to extend runway, reduce cost of capital, and de-risk regulatory and technical milestones without over-relying on equity. FI Group Ireland helps you quantify claimable R&D, map the right grant routes, and build audit-ready evidence.
Speak to an FI Group specialist for a CFO-grade biotech funding map, including cash timing, controls, and risk.
What does “R&D tax for biotech” mean in Ireland?
R&D tax for biotech refers to qualifying scientific and technological work that seeks to resolve uncertainty through systematic investigation, and which meets Ireland’s R&D tax credit criteria. In biotech, this often spans discovery, pre-clinical, CMC, process development, analytical methods, and scale-up, provided the work is not routine and the uncertainty is real.
Biotech CFOs typically see three practical levers:
- Cash acceleration: converting eligible spend into a predictable cashflow profile.
- Governance: aligning technical narratives, cost capture, and controls with Revenue expectations.
- Portfolio clarity: separating genuine R&D from QA, validation-as-usual, and commercial manufacturing.